08:16 AM EDT, 07/31/2024 (MT Newswires) -- Teva Pharmaceutical Industries ( TEVA ) reported Q2 non-GAAP earnings Wednesday of $0.61 per diluted share, up from $0.56 a year earlier.

Analysts polled by Capital IQ expected $0.55.

Net revenue for the quarter ended June 30 was $4.16 billion, compared with $3.88 billion a year earlier.

Analysts surveyed by Capital IQ expected revenue of $4.05 billion.

The drugmaker said it now expects 2024 revenue of $16 billion to $16.4 billion, compared with its prior guidance of between $15.7 billion and $16.3 billion. Analysts surveyed by Capital IQ expect $15.99 billion.

Full-year adjusted EPS guidance was revised to $2.30 to $2.50 from $2.20 to $2.50 previously. Analysts polled by Capital IQ expect $2.46.

Teva shares were up by more than 2% in premarket trading.

Price: 16.50, Change: +0.09, Percent Change: +0.55